Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Available × Neurofibromatoses × Clear all

Status

Completed 27 Recruiting 9 Terminated 4 Active not recruiting 3 Unknown 2 Suspended 1 Not yet recruiting 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Neoplasms 11 Prostatic Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Multiple Myeloma 6 Carcinoma, Non-Small-Cell Lung 6 Sarcoma 5 Recurrence 5 Neuroblastoma 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Leukemia, Myeloid, Acute 4 Stomach Neoplasms 3 Hematologic Neoplasms 3 Glioblastoma 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Pheochromocytoma 2 Osteosarcoma 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroectodermal Tumors, Primitive 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Lymphoma 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05028166 2024-03-15

Individual Patient Compassionate Use of Mirdametinib

SpringWorks Therapeutics, Inc.

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡